EU approval for $PFE $MKGAF $MKGAY BAVENCIO (avelumab)

The European Commission approved Pfizer (PFE) and development/commercialization partner Merck KGaA's (OTCPK:MKGAF) (OTCPK:MKGAY) BAVENCIO (avelumab) ... Market launch to commence soon. Initial launches in Germany and the UK could happen as soon as next month.

Catch up on pharma and biotech news at our Daily Pharma Scoop at SeekingAlpha Marketplace.

USPTO’s ruling favors $LPCN

Lipocine’s (LPCN) shares are up by 2% in early trading on increased volume after it announced a favorable ruling by the USPTO's Patent Trial and Appeal Board (PTAB) regarding its dispute with Clarus Therapeutics.  

Read more such news in our Daily Pharma Scoop at SeekingAlpha Marketplace.

$NTLA up over 8%

Intellia Therapeutics’ (NTLA) shares rose following the news that scientists at UC-Berkeley and Massachusetts General Hospital have found a way to improve the precision of DNA-editing technology CRISPR/Cas9.

Read the full post in our SeekingAlpha Marketplace Daily Pharma Scoop.

$AKTX to advance lead candidate Coversin into Phase 3

Akari Therapeutics (AKTX) had an End-of-Phase 2 meeting with the FDA and announced that they will advance lead candidate Coversin into Phase 3 development for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Q1 2018. 

Shares are up 6% in pre-market.

Read detail in our SeekingAlpha Marketplace Daily Pharma Scoop.

$1.45mn Insider Buy at $ALDX

$1.45mn buy by 10% insider. Shares rose slightly in pre-market.

Check out more insider data in our SeekingAlpha Marketplace Daily Pharma Scoop.

$ESPR Growth Potential Discussed

Esperion’s potential in the statin-intolerant anti-cholesterol market is discussed. 

“In 2015, the FDA guided that ESPR might have to wait until results of their CVOT in 2022 to file their NDA. This was the first time the FDA had ever provided this type of guidance as previous cholesterol drugs had been approved on LDL-C lowering studies alone.”

However...

read the full discussion in our Daily Pharma Scoop at SeekingAlpha Marketplace.

Analyzing $BBH VanEck Vectors Biotech ETF

VanEck Vectors Biotech ETF (BBH) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Biotech 25 Index (MVBBHTR), which is intended to track the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment.

Read full analysis in our Daily Pharma Scoop at SeekingAlpha Marketplace.

$KPTI positive results from phase 2/3

Micro cap Karyopharm Therapeutics (KPTI) announced positive results from its Phase 2/3 clinical trial, SEAL, assessing selinexor ((KPT-330)) in patients with previously treated, advanced, unresectable, dedifferentiated liposarcoma.

Read the full brief in our Daily Pharma Scoop at SeekingAlpha Marketplace.

Is $ADHD worth betting on?

The Alcobra (ADHD) article in Seeking Alpha broadly says that though Alcobra is a company with a failed drug and no future prospects, it has a lot of cash and is selling below its NCAV or net current asset value. 

Read our full take in our SeekingAlpha Marketplace Daily Pharma Scoop.

$ICPT buy opportunity for risk prone investors

Our daily analysis of a stock with a major event/upside: Intercept’s Letter Overblown

Intercept (ICPT) saw a major slump last week, falling 20% from $110 to $85 or so, after the company’s CEO Dr Mark Pruzanski sent a “Dear Doctor” letter out to prescribing physicians of its Ocaliva medication telling them not to prescribe the drug in higher doses than recommended. 

Read the full analysis in our Daily Pharma Scoop at SeekingAlpha Marketplace.